Skip to main content

Table 2 Participants’ clinical characteristics according to anticyclic citrullinated peptide quartile

From: Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX®: a registry study of RA with osteoporosis/fracture

  Group (anti-CCP U/ml)
  I
≤2 (Q1)
(n = 130)
II
>2–60 (Q2)
(n = 127)
III
>60–290 (Q3)
(n = 132)
IV
≥290 (Q4)
(n = 132)
p Value
Anti-CCP, U/mla 0.7 (0.7) 20.0 (35.2) 140.0 (108.0) 340.0 (34.0) <0.0001
Female, n (%)a 114 (87.7) 111 (87.4) 112 (84.9) 110 (83.3) 0.2529
Age, yearsb 57.0 (14.0) 60.0 (14.0) 60.0 (13.5) 61.0 (14.0) 0.0729
BMI, kg/m2b 23.3 (4.2) 22.6 (5.0) 23.0 (5.4) 23.8 (5.1) 0.3731
Disease duration, yearsb 11.0 (13.0)
n = 126
12.0 (13.0)
n = 121
12.0 (15.0)
n = 121
12.0 (11.0)
n = 123
0.8547
Symptom to diagnosis, yearsb 10.0 (8.5)
n = 127
10.0 (8.0)
n = 127
9.0 (10.5)
n = 132
10.0 (11.0)
n = 131
0.9379
DAS28-ESRb 2.7 (1.4)
n = 129
3.1 (1.6) 3.0 (1.6)
n = 131
3.6 (2.0) 0.0001
RF+, n (%)a 22 (16.9) 95 (74.8) 111 (86.1)
n = 129
119 (90.8)
n = 131
<0.0001
RF, IU/mlb 10.3 (1.3) 88.8 (205.5) 125.0 (256.3)
n = 129
146.0 (469.0)
n = 131
<0.0001
ESR, mm/hb 12.5 (14.0) 18.0 (26.0) 17.0 (20.0) 23.0 (34.0) <0.0001
CRP, mg/Lb 1.4 (5.7)
n = 129
3.1 (8.2) 3.1 (8.6) 3.2 (9.2)
n = 131
0.0012
Current smoking, n (%)a 4 (3.1) 6 (4.7) 11 (8.3) 14 (10.6) 0.0075
Glucocorticoid users, n (%)a 107 (82.3) 113 (89.0) 117 (88.6) 115 (87.1) 0.2876
Comorbidity, n (%)a 80 (61.5) 83 (65.4) 75 (56.8) 77 (58.3) 0.3448
Fall in previous year, n (%)a 22 (17.3)
n = 127
26 (20.6)
n = 126
28 (22.1)
n = 127
21 (16.5)
n = 127
0.9521
BMD, g/cm2
 Spine (L1–L4)a 0.893 (0.195)
n = 128
0.826 (0.211)
n = 123
0.854 (0.223)
n = 122
0.856 (0.180)
n = 128
0.0394
 Hip (total)c 0.807 ± 0.148
n = 124
0.741 ± 0.122
n = 122
0.786 ± 0.148
n = 125
0.786 ± 0.157
n = 126
0.0041
 FNb 0.651 (0.149)
n = 124
0.602 (0.146)
n = 122
0.615 (0.145)
n = 125
0.6145 (0.139)
n = 126
0.0033
Previous
fracture, n (%)a
20 (15.4) 28 (22.1) 23 (17.4) 26 (19.7) 0.5827
Osteoporosis,a,d n (%) 27 (21.1)
n = 128
45 (36.0)
n = 125
38 (29.9)
n = 127
40 (31.0)
n = 129
0.1866
Current anti-osteoporosis, n (%)a 18 (13.9) 34 (26.8) 25 (19.0) 27 (20.6) 0.4225
Majorb,e 11.0 (13.2) 17.0 (19.6) 15.0 (17.4) 14.0 (19.7) 0.0067
Hipb,f 3.1 (6.3) 6.1 (9.8) 4.6 (9.0) 4.9 (9.4) 0.0013
  1. Abbreviations: BMI Body mass index, Anti-CCP Anticitrullinated protein antibodies, RF Rheumatoid factor, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, DAS28-ESR Disease Activity Score in 28 joints based on erythrocyte sedimentation rate, BMD Bone mineral density, FN Femoral neck
  2. a Absolute number (percentage)
  3. b Median (interquartile range)
  4. c Mean ± SD
  5. d FN T-score less than or equal to −2.5
  6. e Ten-year probability of major fracture
  7. f Ten-year probability of hip fracture